Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Terminated Phase 1Phase 2 Interventional

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

NCT01025648
View directory record Official record
Conditions
Asthma
Interventions
E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 Placebo, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg, epinephrine inhalation aerosol, CFC propelled, E004 (epinephrine inhalation aerosol), 160 mcg
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Jose, California • Stockton, California
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 25, 2026, 2:08 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

NCT01508910
View directory record Official record
Conditions
Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions
Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488
View directory record Official record
Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
Dupilumab
Drug
Lead sponsor
Rochester General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

NCT05413668
View directory record Official record
Conditions
Healthy
Interventions
RVP-001, Placebo
Drug
Lead sponsor
Reveal Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 25, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

NCT07601074
View directory record Official record
Conditions
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions
Lopinavir / ritonavir
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
22 Years to 50 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780424
View directory record Official record
Conditions
COVID-19
Interventions
BRII-196, BRII-198, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
76
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

NCT04543591
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Placebo, Best supportive care
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 100 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Tampa, Florida • Grosse Pointe Farms, Michigan • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

NCT01205503
View directory record Official record
Conditions
Breast Cancer, Non-Hodgkin's Lymphoma
Interventions
Mesna, Saline, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 25, 2026, 2:08 PM EDT
Withdrawn Phase 2 Interventional

Vitamin C for Severe Thermal Injuries

NCT01587261
View directory record Official record
Conditions
Severe Thermal Injury, Greater Than 20% TBSA
Interventions
Vitamin C, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 25, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

NCT06436742
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, CMS
Interventions
ARGX-119, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications

NCT01096290
View directory record Official record
Conditions
Constipation
Interventions
lubiprostone, Matched placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

NCT05432479
View directory record Official record
Conditions
Infantile Colic
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
The Archer-Daniels-Midland Company
Industry
Eligibility
3 Weeks to 12 Weeks
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Study of CB-183,315 in Participants With Clostridium Difficile Infection

NCT01085591
View directory record Official record
Conditions
Clostridium Difficile Infection, Diarrhea
Interventions
CB-183,315, Placebo, Vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971
View directory record Official record
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 25, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation

NCT04582409
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
HSY244, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty

NCT02121392
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Nerve Block
Interventions
Adductor Canal Nerve Block Catheter, Adductor Canal Nerve Block Sham Catheter, Bupivacaine
Device · Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 85 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 25, 2026, 2:08 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty

NCT04585230
View directory record Official record
Conditions
Pain, Joint, Pain, Postoperative, Total Knee Arthroplasty
Interventions
CBD, Mineral Oil, Placebo
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 25, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

NCT07772492
View directory record Official record
Conditions
Severe Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 2:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Early Use of Vasopressin in Post-Fontan Management

NCT03088345
View directory record Official record
Conditions
Circulatory Perfusion Disorder, Congenital Heart Disease, Single-ventricle
Interventions
Vasopressin, Arginine, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Weeks to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 25, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

NCT05275686
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 25, 2026, 2:08 PM EDT